| 替吉奥治疗晚期乳腺癌的研究进展 |
| |
| 引用本文： | 郑婷,钱其军.替吉奥治疗晚期乳腺癌的研究进展[J].药学实践杂志,2015,33(6):557-560. |
| |
| 作者姓名： | 郑婷 钱其军 |
| |
| 作者单位： | 福建医科大学第一临床医学院, 福建 福州 350108;第二军医大学附属东方肝胆外科医院生物治疗科、病毒基因治疗实验室, 上海 200438,第二军医大学附属东方肝胆外科医院生物治疗科、病毒基因治疗实验室, 上海 200438 |
| |
| 基金项目： | 国家科技重大专项(No.2013ZX10002-010-007) |
| |
| 摘 要： | 替吉奥(S-1)是第三代氟尿嘧啶衍生物的口服抗癌剂,毒副作用小、疗效确切、给药方便。在大量的临床试验及不断的临床应用中,其展示出对晚期乳腺癌(advanced breast cancer,ABC)治疗的良好效果,将来有望成为乳腺癌治疗的一线化疗药物。
|
| 关 键 词： | 替吉奥(S-1) 晚期乳腺癌 化疗药物 |
| 收稿时间： | 2/9/2015 12:00:00 AM |
| 修稿时间： | 6/4/2015 12:00:00 AM |
Progress on S-1 in the treatment of advanced breast cancer |
| |
| ZHENG Ting and QIAN Qijun.Progress on S-1 in the treatment of advanced breast cancer[J].The Journal of Pharmaceutical Practice,2015,33(6):557-560. |
| |
| Authors: | ZHENG Ting and QIAN Qijun |
| |
| Institution: | First Clinical Medical College, Fujian Medical University, Fuzhou 350108, China;Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China and Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China |
| |
| Abstract: | S-1 is the third generation of fluorouracil derivative anti-cancer agent with small side effects, efficacy, and drug delivery is convenient.In a large number of clinical trials and continuous clinical application, it showed the good effect for the treatment of advanced breast cancer, which was expected to become the first-line chemotherapy drug for breast cancer treatment in the future. |
| |
| Keywords: | S-1 advanced breast cancer chemotherapy drug |
|
| 点击此处可从《药学实践杂志》浏览原始摘要信息 |
| 点击此处可从《药学实践杂志》下载免费的PDF全文 |
|
